Please use this identifier to cite or link to this item: http://111.93.178.142:25000/jspui/handle/123456789/5197
Full metadata record
DC FieldValueLanguage
dc.contributor.authorSuresh Bairi-
dc.date.accessioned2026-06-08T06:09:37Z-
dc.date.available2026-06-08T06:09:37Z-
dc.date.issued2026-06-08-
dc.identifier.urihttp://111.93.178.142:25000/jspui/handle/123456789/5197-
dc.descriptionVol. 36, No. 1, p 23en_US
dc.language.isoenen_US
dc.subjectOxadiazole-imidazole hybridsen_US
dc.subjectMolecular dockingen_US
dc.subjectEpidermal growth factor receptor/human epidermal growth factor recrptor 2 inhibitorsen_US
dc.subjectIn silico absrptionen_US
dc.subjectdistributionen_US
dc.subjectmetabolismen_US
dc.subjectexcreation proflingen_US
dc.subjectAnticancer drug designen_US
dc.titleDocking studies of 1,2,4- oxadiazole incorporated (2-(oxazol)-1H-imidazole) derivatives a anticancer agentsen_US
dc.typeOtheren_US
Appears in Collections:Vol. 36, No. 1, 2026

Files in This Item:
File Description SizeFormat 
1.pdfVol. 36, No. 1, p 23139.55 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.